Coherus Oncology, Inc. Common Stock (CHRS) is a publicly traded Healthcare sector company. As of September 21, 2026, CHRS trades at $1.33 with a market cap of $208.58M and a P/E ratio of -1.25. CHRS moved -1.85% today. Year to date, CHRS is -4.93%; over the trailing twelve months it is -11.76%. Its 52-week range spans $0.71 to $2.62. Analyst consensus is strong buy with an average price target of $7.75. Rallies surfaces CHRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for CHRS combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $1.33 |
| Market Cap | $208.58M |
| P/E Ratio | -1.25 |
| EPS | $-1.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.62 |
| 52-Week Low | $0.71 |
| Volume | 284 |
| Avg Volume | 0 |
| Revenue (TTM) | $50.94M |
| Net Income | $-132.13M |
| Gross Margin | 68.94% |
4 analysts cover CHRS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.75.